scispace - formally typeset
V

Vikas Kumar

Researcher at University of Agriculture, Faisalabad

Publications -  60
Citations -  1173

Vikas Kumar is an academic researcher from University of Agriculture, Faisalabad. The author has contributed to research in topics: Proinflammatory cytokine & Solid lipid nanoparticle. The author has an hindex of 13, co-authored 60 publications receiving 572 citations. Previous affiliations of Vikas Kumar include Sam Higginbottom Institute of Agriculture, Technology and Sciences.

Papers
More filters
Journal ArticleDOI

Risk of colorectal cancer in inflammatory bowel diseases.

TL;DR: Many common factors influencing the onset and advancement of IBD and CRC including the alterations in gut microbiota, changes in the interleukin pathways and tumour necrosis factor are described.
Journal ArticleDOI

Antiviral effects of probiotic metabolites on COVID-19.

TL;DR: Multi-way options either by blocking RBD on S proteins or interaction of S protein with ACE2 receptor proteins or inhibiting RdRp to counter any effect of COVID-19 by Plantaricin molecules are presented, paving a way that can be useful in the treatment of CO VID-19 until some better option will be available.
Journal ArticleDOI

Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin.

TL;DR: Histopathological evaluation indicated reduced incidence of hepatic nodules, necrosis formation, infiltration of inflammatory cells, blood vessel inflammation and cell swelling with RT-PLGA-NP treatment along with considerable downregulation in the levels of proinflammatory cytokines.
Journal ArticleDOI

Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies

TL;DR: The study successfully established the development and characterization of UFG-PLGA-NP with noticeable effect against both in vivo and in vitro models, and demonstrated that such polymer-loaded delivery systems of U FG can be a better option and can be further explored to improve the clinical outcomes against hepatic cancer.